SCHEMBL23211853

SCHEMBL23211853

O=C(O)N1CC(c2ccc(Cl)cn2)C1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCD5 Q86SK9 2/20 0.45
SCD O00767 1/20 0.45
HSD11B1 P28845 1/20 0.39
GRM5 P41594 2/20 0.39
APLNR P35414 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PROKR1 Q8TCW9 2/20 0.37
USP30 Q70CQ3 1/20 0.37
CNR2 P34972 1/20 0.36
PTK2 Q05397 1/20 0.36
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
NFKB1 P19838 1/20 0.35
RAB9A P51151 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19376023 0.88 HSD11B1 (0.49) SCD5SCDHSD11B1APLNRPROKR1
SCHEMBL23211035 0.84 IDO1 (0.43) SCD5SCDHSD11B1APLNRNPC1
SCHEMBL25301341 0.82 CNR1 (0.45) CNR2NPC1RAB9A
SCHEMBL16007873 0.81 KDM5A (0.49) HSD11B1GRM5PROKR1USP30NPC1
SCHEMBL17729604 0.81 KDM5A (0.47) HSD11B1L3MBTL1USP30CNR2SMN1; SMN2
SCHEMBL17729535 0.81 ALDH1A1 (0.43) GRM5L3MBTL1USP30NPC1MAPT
SCHEMBL25252769 0.80 FASN (0.44) PROKR1
SCHEMBL21381749 0.79 MEN1 (0.48) USP30LMNATP53SMN1; SMN2
SCHEMBL30567976 0.79 MEN1 (0.48) USP30LMNATP53SMN1; SMN2
SCHEMBL23453680 0.78 USP30 (0.36) SCD5L3MBTL1USP30CNR2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 EP disclosed
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC SCD5 162/4885SCD 115/4885HSD11B1 269/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC SCD5 162/4885SCD 115/4885HSD11B1 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.